Shasun Pharmaceuticals aims to double its turnover by 2015

19 Apr 2012 Evaluate

Shasun Pharmaceuticals has set a target to double its turnover to Rs 2,000 crore by 2015. Moreover, the company’s revenue has jumped over 75% to cross Rs 1,000 crore during the financial year ending March this year. The previous year’s revenue was Rs 568 crore with nearly 90% from exports.

The company, which invested Rs 83 crore last fiscal in its operations, is planning to invest around Rs 250 crore for capacity expansion in 2012-13, including setting up of a multiproduct facility in Visakhapatnam, Andhra Pradesh, and upgrading existing facilities.

The formulations business under Crams is expected to grow from the current Rs 80 crore to Rs 400 crore, and its UK subsidiary, Shasun Pharma Solutions that is exclusively for Crams, is expected to clock in around Rs 500 crore in 2014-15 from Rs 350 crore at present.

While, the active pharmaceutical ingredients (API) business is expected to grow from Rs 400 crore now to Rs 600 crore while the API business for Crams and custom synthesis would go up from Rs 90 crore to Rs 250 crore by the fiscal 2014-15. The upcoming plant at Vizag would generate a business of Rs 300 crore by the time. The biotech business would grow from Rs 3 crore at present to Rs 25 crore.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×